{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:58:22Z","timestamp":1777481902336,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2014,2]]},"abstract":"\n Purpose:<\/jats:title>\n \n To report a comparison of SPECT\/CT technique with standard blood-based dosimetry methodology in a cohort of non-Hodgkin lymphoma (NHL) patients treated with\n 131<\/jats:sup>\n I-rituximab anti-CD20 chimeric monoclonal antibody.\n <\/jats:p>\n <\/jats:sec>\n \n Methodology:<\/jats:title>\n \n Red marrow uptake was measured directly using serial quantitative whole-body imaging in conjunction with SPECT\/CT in a cohort of 23 patients undergoing routine\n 131<\/jats:sup>\n I-rituximab radioimmunotherapy of NHL. Absorbed dose measurements were then compared with radiation doses calculated using standard peripheral blood counting methodology.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Activity clearance from whole body of 88.7 hours measured by imaging\n 131<\/jats:sup>\n I-rituximab was significantly slower (\n p<\/jats:italic>\n <0.001) than the mean effective half-life clearance of 60.8 hours calculated from the sampling peripheral blood. The mean activity concentrations in bone marrow measured using SPECT\/CT, and by blood sampling, extrapolated to the time of administration, were, however, concordant. The absorbed self-dose in red marrow, measured using imaging, was 1.02 Gy compared with the dose (0.81 Gy) calculated from blood sampling. Neutrophil toxicity correlated with absorbed dose by SPECT\/CT imaging (\n p<\/jats:italic>\n =0.01), whereas the blood sampling method demonstrated no correlation with any parameters of hematological toxicity.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n \n Radiation dose to red marrow from\n 131<\/jats:sup>\n I-rituximab is inherently underestimated by standard indirect peripheral blood counting methods. Personalized marrow dosimetry by quantitative gamma imaging more accurately predicts of hemopoietic myelotoxicity by direct measurement of the bone marrow activity concentration of\n 131<\/jats:sup>\n I-rituximab.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1089\/cbr.2013.1490","type":"journal-article","created":{"date-parts":[[2013,10,17]],"date-time":"2013-10-17T09:28:38Z","timestamp":1382002118000},"page":"18-25","source":"Crossref","is-referenced-by-count":4,"title":["Personalized Dosimetry of\n 131<\/sup>\n I-Rituximab Radioimmunotherapy of Non-Hodgkin Lymphoma Defined by Pharmacokinetics in Bone Marrow and Blood"],"prefix":"10.1177","volume":"29","author":[{"given":"Jan A.","family":"Boucek","sequence":"first","affiliation":[{"name":"The University of Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Harvey","family":"Turner","sequence":"additional","affiliation":[{"name":"The University of Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,2,1]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1089\/108497803322287583"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-269753"},{"key":"e_1_3_3_4_2","volume-title":"2011 ASH Annual Scientific Meeting","author":"McQuillan AD","unstructured":"McQuillan AD, , Macdonald WBG, , Leahy MF, et al. First-line radioimmunotherapy of newly diagnosed, advanced follicular non-Hodgkin lymphoma with 131I-rituximab: The INITIAL study. 2011 ASH Annual Scientific Meeting;Abstract 3719."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn172"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.3470"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.7.1974"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-004-1692-9"},{"key":"e_1_3_3_9_2","first-page":"1245","article-title":"Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy","volume":"43","author":"Shen S","year":"2002","unstructured":"Shen S, , Meredith RF, , Duan J, et al. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy. J Nucl Med, 2002; 43:1245.","journal-title":"J Nucl Med"},{"key":"e_1_3_3_10_2","first-page":"465","article-title":"Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials","volume":"44","author":"Wiseman GA","year":"2002","unstructured":"Wiseman GA, , Kornmehl E, , Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials. J Nucl Med, 2002; 44:465.","journal-title":"J Nucl Med"},{"key":"e_1_3_3_11_2","first-page":"1725","article-title":"Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: A multiinstitutional comparison","volume":"45","author":"Wessels BW","year":"2004","unstructured":"Wessels BW, , Bolch WE, , Bouchet LG, et al. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: A multiinstitutional comparison. J Nucl Med, 2004; 45:1725.","journal-title":"J Nucl Med"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003072-199502000-00005"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1422-4"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2005.20.126"},{"key":"e_1_3_3_15_2","first-page":"2102","article-title":"Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body","volume":"40","author":"Shen S","year":"1999","unstructured":"Shen S, , DeNardo GL, , Sgouros G, et al. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med, 1999; 40:2102.","journal-title":"J Nucl Med"},{"key":"e_1_3_3_16_2","first-page":"1519","article-title":"Side effects of \u201crational dose\u201d iodine-131 therapy for metastatic well-differentiated thyroid carcinoma","volume":"27","author":"Van Nostrand D","year":"1986","unstructured":"Van Nostrand D, , Neutze J, , Atkins F. Side effects of \u201crational dose\u201d iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med, 1986; 27:1519.","journal-title":"J Nucl Med"},{"key":"e_1_3_3_17_2","first-page":"1549","article-title":"Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer","volume":"45","author":"de Keizer B","year":"2004","unstructured":"de Keizer B, , Hoekstra A, , Konijnenberg MW, et al. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. J Nucl Med, 2004; 45:1549.","journal-title":"J Nucl Med"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00255498"},{"key":"e_1_3_3_19_2","first-page":"689","article-title":"Bone marrow dosimetry for radioimmunotherapy","volume":"34","author":"Sgouros G","year":"1993","unstructured":"Sgouros G. Bone marrow dosimetry for radioimmunotherapy. J Nucl Med, 1993; 34:689.","journal-title":"J Nucl Med"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.056036"},{"key":"e_1_3_3_21_2","volume-title":"ICRP publication 70","author":"ICRP 70","year":"1995","unstructured":"ICRP 70. Basic Anatomical and Physiological Data for Use in Radiological Protection: The Skeleton. ICRP publication 70. Oxford, UK: International Commission on Radiological Protection, 1995."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.100123"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1141-x"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.096453"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008416911099"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-175653"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.6.1851"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cbr.2013.1490","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2013.1490","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2013.1490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:14:04Z","timestamp":1777385644000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cbr.2013.1490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1089\/cbr.2013.1490"],"URL":"https:\/\/doi.org\/10.1089\/cbr.2013.1490","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}